We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.62 | -8.83% | 6.40 | 6.00 | 6.80 | 6.80 | 6.64 | 6.66 | 863,426 | 16:35:26 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.78 | 13.69M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 16/11/2020 10:45 | The point about the mRNA is that it's very unstable and doesn't survive for long in the body. The messenger ends up getting shot. | stimulationengineer | |
| 16/11/2020 10:35 | Kooba I can't argue that point, however don't you think it's a huge coincidence the news was announced that very morning?? | blakieboy7 | |
| 16/11/2020 10:24 | Pfizer confirmed the transaction had been filed but said it was an automated process, set up earlier this year under a trading plan by its boss. Under the system, shares are sold provided they go above a pre-agreed price.https://www.in | kooba | |
| 16/11/2020 10:16 | rumours about India clearly not having the desired effect... | sloppyjoe2 | |
| 16/11/2020 10:14 | Kooba you're telling me it's just coincidence he happened to sell his shares the day the news was announced?! Give me strength | blakieboy7 | |
| 16/11/2020 10:12 | It was all pre planned months ago for guys personal financial planning irrespective of outcome of vaccine ..so was out of his hands the timing of sales. | kooba | |
| 16/11/2020 09:59 | Needs some more positive news from the company now ! The vaccine rumours are just killing it atm !! | paradise city |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
